Natco Pharma has informed that the Trading Window for dealing in the securities of the Company would remain closed for the Directors, Designated Persons, their immediate relatives and all other connected persons covered in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from January 1, 2023 to till 48 hours after the declaration of the Financial Results of the Company for the quarter ending on December 31, 2022. The date of the Board Meeting for declaration of the financial results of the Company for the quarter ending on December 31, 2022 will be intimated in due course of time.
The above information is a part of company’s filings submitted to BSE.